Changeflow GovPing Pharma & Drug Safety Oral Testosterone Ester Composition for Treatin...
Routine Notice Added Final

Oral Testosterone Ester Composition for Treating Liver Diseases

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office granted Patent EP3824296A1 to Lipocine Inc. covering an oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases. The patent designates 33 European Patent Convention states including Germany, France, the United Kingdom, Italy, and Spain. Inventors include Patel, Chidambaram, Nachaegari, Byrne, Kim, and Baker.

What changed

EPO granted patent EP3824296A1 to Lipocine Inc. covering oral pharmaceutical compositions containing testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases (A61P 1/16). The patent application was published under the A1 kind code indicating it includes the search report.

Pharmaceutical companies developing liver disease treatments should review this patent for potential freedom-to-operate concerns. Competitors in the testosterone or liver disease therapeutic space should monitor this IP family for potential overlap with their own development programs. Patent prosecution history may provide insights into claim scope and examiner positions during examination.

What to do next

  1. Monitor patent portfolio for potential licensing opportunities
  2. Review freedom-to-operate landscape for competing liver disease therapies

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ORAL PHARMACEUTICAL COMPOSITION COMPRISING TESTOSTERONE TRIDECANOATE AND/OR TESTOSTERONE DODECANOATE FOR TREATING LIVER DISEASES

Publication EP3824296A1 Kind: A1 Apr 01, 2026

Applicants

Lipocine Inc.

Inventors

PATEL, Mahesh V., CHIDAMBARAM, Nachiappan, NACHAEGARI, Satish K., BYRNE, Burke, KIM, Kilyoung, BAKER, Jonathan A.

IPC Classifications

A61K 31/201 20060101AFI20251027BHEP A61K 31/355 20060101ALI20251027BHEP A61K 31/568 20060101ALI20251027BHEP G01N 33/74 20060101ALI20251027BHEP H01J 49/00 20060101ALI20251027BHEP A61P 1/16 20060101ALI20251027BHEP G01N 33/68 20060101ALI20251027BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP3824296A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant IP registration Therapeutic composition
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!